SynthesisPloS one2025
The association of sarcopenia, possible sarcopenia and cognitive impairment: A systematic review and meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review and Meta-analysis on the association between sarcopenia and cognitive impairment in middle-aged and older adults from Latin America.The journal of nutrition, health & aging · 2026Pooled it
- Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities.Nutrients · 2026Review
- Heterogeneous trajectories of appendicular skeletal muscle mass change and cognitive impairment in community-dwelling middle-aged and older adults.Scientific reports · 2026Article
- Article
- Muscle Ultrasound Parameters and Cognitive Function in H‑type Hypertension: A Cross-Sectional Study.Clinical interventions in aging · 2026Article
- Risk Factors of Caregiver Burden in Patients With Cognitive Dysfunction: A Scoping Review.Brain and behavior · 2026Article
- Sarcopenia in the Aging Process: Pathophysiological Mechanisms, Clinical Implications, and Emerging Therapeutic Approaches.International journal of molecular sciences · 2025Review
- Association between residential proximity to major roadways and low muscle mass among Chinese older adults: a nationwide cross-sectional study.BMC public health · 2025Article
- An Association Between Possible Sarcopenia as an Early Marker and Mild Cognitive Impairment: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2025Article
- Sarcopenia and cognitive performance in hospitalized older adults: evidence of an association.Frontiers in dementia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe study aimed to investigate the relationship between sarcopenia, possible sarcopenia, and cognitive impairment, and to analyze the impact of potential moderating factors.
methodsA comprehensive search was conducted on PubMed, EmBase, Web of Science, Cochrane Library, CNKI, Wanfang Databases, VIP and SinoMed from inception until March 2025. The quality of cross-sectional studies was assessed using the Agency for Healthcare Research and Quality Scale, while the Newcastle-Ottawa scale was used to assess the quality of included case-control and cohort studies. Subgroup analyses and meta-regression were employed to explore potential moderating variables and heterogeneity.
resultsA total of 31 studies were included in this systematic review, of which 27 studies were quantitatively analyzed. The meta-analysis revealed that both sarcopenia and possible sarcopenia significantly associated with cognitive impairment (OR=1.88, 95%CI = 1.71-2.08), (OR=1.96, 95%CI = 1.50-2.58). Subgroup analyses revealed a stronger association between sarcopenia and cognitive impairment in specific demographics: among females with sarcopenia (OR=3.22, 95%CI = 1.23-8.40), in Asian populations (OR=1.96, 95%CI = 1.76-2.18), and within hospital settings (OR=3.12, 95%CI = 2.18-4.48). These findings underscore the influence of gender, ethnicity, and healthcare environment on the relationship between sarcopenia and cognitive impairment. An assessment of publication bias within studies providing adjusted odds ratios indicated potential bias. However, sensitivity analyses and trim-and-filling analyses confirmed the robustness of our findings, suggesting that the observed associations remain reliable despite the presence of publication bias.
conclusionsIndividuals with sarcopenia or possible sarcopenia have approximately twice the odds of developing cognitive impairment compared to those without sarcopenia. Implementing systematic screening and targeted interventions for possible sarcopenia patients is essential to prevent from cognitive decline. Specifically, healthcare professionals should focus on women and inpatients with sarcopenia, employing proactive measures to avert cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.